Post
Horizon doses first participant in Phase I gout therapy trial
The Phase I trial will evaluate the pharmacokinetics, tolerability, pharmacodynamics, and safety of HZN-457.
The Metaverse: Macroeconomic trends
Free Report The Metaverse is becoming a reality – adapt to meet it Although the term resists single definition, the…
Biosimilars hit a turning point as they expand outside oncology
Biosimilar drugs are biological medicines that are extremely similar to another biological medicine that has already been licensed for use.
Health Canada grants CTA authorisation for QurAlis’ ALS therapy
Assessing the safety and tolerability of varying doses of QRL-201 in ALS patients is the primary objective of the trial.
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
The Brazilian pharma market: Key information and what may change
Brazil has the largest pharmaceutical market in Latin America, and recent political changes have raised speculation about what other changes could be in store. We take a look at the country’s pharma market and explore what could be around the corner in terms of legislation.
Regenxbio concludes subject dosing in Phase I/II severe MPS I trial
Assessing the safety of RGX-111 is the primary endpoint of the trial.
BioAge Labs reports positive trial results for the treatment of muscle atrophy
The company plans to begin a Phase II trial in the prevention of ICU diaphragmatic atrophy and critical illness myopathy.
Relmada reports data from trial of REL-1017 for major depressive disorder
The RELIANCE I trial results showed that REL-1017-treated patients had a 15.1 point reduction in the MADRS.
Sitero and CRIO partner to improve patient safety in trials
The collaboration will remove the need for redundant, manual, and error-prone activities across the clinical lifecycle.
Suvoda unveils electronic clinical outcome assessments design toolkit
The toolkit is created to integrate with the Suvoda IRT and eConsent, and also address the historical inadequacies that impact eCOA.
Next on diversity: inclusion of participants with cognitive impairment in clinical trials
Clinical Trials Arena dives into a frequently forgotten aspect of clinical trial diversity: participation of people with cognitive disabilities.